Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Equity (2016 - 2025)

Historic Return on Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.59%.

  • Viridian Therapeutics, Inc.\DE's Return on Equity fell 1800.0% to 0.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.59%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.48% for FY2024, which is 800.0% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Return on Equity stood at 0.59% for Q3 2025, which was down 1800.0% from 0.61% recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Equity peaked at 0.32% during Q4 2022, and registered a low of 1.3% during Q2 2021.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Return on Equity had a median value of 0.49% in 2022 and averaged 0.6%.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 11700bps in 2021, then tumbled by -3300bps in 2023.
  • Viridian Therapeutics, Inc.\DE's Return on Equity (Quarter) stood at 0.41% in 2021, then increased by 20bps to 0.32% in 2022, then tumbled by -103bps to 0.66% in 2023, then surged by 40bps to 0.39% in 2024, then crashed by -52bps to 0.59% in 2025.
  • Its last three reported values are 0.59% in Q3 2025, 0.61% for Q2 2025, and 0.48% during Q1 2025.